Humabiologics
Humabiologics produces and sells native human-derived collagen, gelatin, and extracellular matrix biomaterials — sourced from AATB-accredited tissue banks under ISO 13485 cGMP standards — to academic researchers, pharmaceutical companies, and CROs in regenerative medicine, 3D bioprinting, and drug testing applications globally.
- Company typePrivate
- Founded2018
- HeadquartersPhoenix, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Humabiologics does
Humabiologics is a Phoenix-based regenerative medicine company founded in 2018 that produces and sells native human-derived biomaterials — including collagen types I, II, IV, and V, gelatin, elastin, universal extracellular matrix (ECM), and tissue- and organ-specific ECM coatings — for use in research, 3D bioprinting, organoid and organ-on-chip development, and drug testing. Products are sourced from AATB-accredited tissue banks and manufactured under an ISO 13485:2016-certified quality system in an FDA-registered, cGMP-compliant facility, with two USPTO patents granted in November 2024 covering proprietary collagen and gelatin production processes. The portfolio spans 59 SKUs organized under sub-brands such as HumaDerm, HumaDerMA, HumaMatrix, Huma OsteoGelatin/OsteoGelMA, HumaElastin, and HumaOrganoMatrix.
The company sells primarily through a direct-to-researcher e-commerce storefront priced at unit levels ($95–$485 per SKU), complemented by a global distributor network covering tier-1 life science suppliers (Fisher Scientific, VWR, Millipore Sigma) in North America and dedicated regional partners across Europe (Ourobionics, Regemat 3D, Brinter, URMAT Biomedical) and Asia (Funakoshi, BestoBio, NO.1 Smart Technology, GrandBio, FoliBio). Named end-customers include major pharmaceutical firms (Novo Nordisk, Roche), academic centers (Yale, Rice, Ohio State, Scripps), and contract research organizations (Charles River Laboratories, Lonza), serving a horizontally diversified customer base across regenerative medicine, pharma/biotech, and CRO segments.
Cumulatively, Humabiologics has disclosed approximately $6.5M in funding ($1M seed in 2020, up to $3M exempt offering in 2022, and a $2.5M NSF grant in January 2025) and in November 2025 expanded operations to Winston-Salem, North Carolina's Innovation Quarter to develop and manufacture finished medical devices from native human collagen in collaboration with the Wake Forest Institute for Regenerative Medicine — a strategic pivot from a pure biomaterial supplier toward vertically integrated device development.
Humabiologics firmographics
Firmographics- Name
- Humabiologics
- Legal name
- Humabiologics, Inc.
- Website
- https://humabiologics.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Humabiologics produces and sells native human-derived collagen, gelatin, and extracellular matrix biomaterials — sourced from AATB-accredited tissue banks under ISO 13485 cGMP standards — to academic researchers, pharmaceutical companies, and CROs in regenerative medicine, 3D bioprinting, and drug testing applications globally.
- Ownership category
- akta.pro rank
Humabiologics industry classification
Industry- Product category
- Regenerative Medicine Biomaterials
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)
- akta.pro secondary industries
- 3D Bioprinting & Biofabrication (HLAAAGAC), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Humabiologics is headquartered
LocationHeadquarters
- HQ city
- Phoenix
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Humabiologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Biomaterial product sales: Direct sales of human-derived collagen and ECM products to researchers, with products sold at unit prices. One-time purchase model for research products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard per-unit pricing for all products |
Go-to-market motion3 records
Distribution channels12 records
Marketing channels7 records
Humabiologics product offering
Product offeringCore offering
Humabiologics manufactures and sells native human-derived biomaterials — including collagen (Types I, II, IV, V), gelatin, elastin, and tissue- and organ-specific extracellular matrix (ECM) products — for regenerative medicine research. Products are produced from donated human tissues sourced from AATB-accredited tissue banks under ISO 13485 cGMP standards and sold as research reagents in solution, lyophilized, insoluble, methacrylated, and pre-coated cultureware formats. The portfolio supports applications such as 2D/3D cell culture, organoids, bioprinting, bioinks, disease modeling, organ-on-chip, and drug testing.
Product overview
Humabiologics is a biotechnology company offering a comprehensive portfolio of native human-derived biomaterials for regenerative medicine research. The core product lines include: (1) HumaDerm collagen products spanning Type I, II, IV, and V collagens from human skin and birth tissue, available as solutions, lyophilized powders, and insoluble formats; (2) HumaDerMA methacrylated collagen for photocrosslinking applications; (3) Huma OsteoGelatin and Huma OsteoGelMA gelatin products for bioink and 3D bioprinting; (4) HumaMatrix universal ECM in multiple formulations; (5) Tissue-specific ECM coatings (BoneMatrix, CartiMatrix, TenoMatrix, MyoMatrix, DermiMatrix, AdipoMatrix); (6) Organ-specific ECM coatings (HepatoMatrix, PneumoMatrix, CardioMatrix, NephroMatrix, PancreoMatrix); (7) HumaElastin matrix protein; and (8) Pre-coated cultureware products. The portfolio is designed to enable research applications including regenerative medicine, organoids, drug testing, 2D/3D cell culture, disease modeling, organ-on-a-chip, bioprinting, and bioinks. Products are GMP-compliant, ISO 13485 certified, and sourced exclusively from AATB-accredited tissue banks.
Differentiator
Problem solved
Functional benefit
Brands
- HumaDerm: Human skin collagen type I products - solution, lyophilized, and insoluble forms for cell culture and 3D hydrogel applications
- HumaMatrix
- HumaDerMA
- Huma OsteoGelatin
- Huma OsteoGelMA
- HumaElastin
- HumaOrganoMatrix
- HumaPneumoMatrix Coat
- HumaHepatoMatrix Coat
Products and services
- HumaDerm Collagen Type I (Solution) Native human skin collagen type I solution at 3 mg/ml, 6 mg/ml, and 10 mg/ml concentrations used by researchers for cell culture and 3D hydrogel applications.
- HumaDerm Collagen Type I (Lyophilized) Freeze-dried native human skin collagen type I in 25 mg, 50 mg, and 100 mg sizes for coating tissue culture surfaces or preparing hydrogels in research workflows.
- HumaDerm Insoluble Collagen Type I Insoluble native human skin collagen type I, lyophilized, designed for tissue engineering scaffold preparation.
- HumaDerMA Methacrylated Collagen Type I Methacrylated human skin collagen type I that can be photocrosslinked for tunable 3D gel applications including 3D bioprinting and tissue engineering research.
- HumaDerm Coated Cultureware Pre-coated tissue culture plates, flasks, and dishes with human skin collagen type I supplied ready-to-use for cell attachment and growth applications.
- HumaDerm Collagen Type II Native human cartilage collagen type II solution at 1 mg/ml targeted at cartilage research and joint-related applications.
- HumaDerm Collagen Type IV Native human birth tissue-derived collagen type IV, lyophilized, intended for basement membrane research.
- HumaDerm Collagen Type V Native human birth tissue-derived collagen type V solution for connective tissue research.
- Huma OsteoGelatin Native human-derived gelatin available in high bloom and medium bloom strengths for bioink development and tissue engineering applications.
- Huma OsteoGelMA Methacrylated human gelatin that can be photocrosslinked for 3D bioprinting and biofabrication research.
Companies that use Humabiologics
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
Humabiologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Humabiologics partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- Wake Forest Institute for Regenerative Medicine (WFIRM)coreStrategic partnership for clinical collaboration and device innovation. WFIRM is a leading institution in regenerative medicine research, providing clinical expertise and research capabilities for product development and validation.
- Piedmont Triad Regenerative Medicine Engine (PTRME)coreGrant partnership funded by NSF supporting regenerative medicine research and development initiatives in the Piedmont Triad region of North Carolina.
- Allegro 3DcorePartnership focused on human bioinks for 3D bioprinting applications, combining Humabiologics' human-derived materials with Allegro 3D's bioprinting technology.
- PuredyneminorStrategic partnership for expanded market reach and potential product integration in the regenerative medicine space.
- OurobionicscoreEuropean distribution partner handling sales and distribution of Humabiologics human bioinks and biomaterials across European markets.
- FunakoshicoreJapan distribution partner responsible for sales and distribution of Humabiologics products in the Japanese market.
- BestoBiocoreChina distribution partner handling sales and distribution of Humabiologics products in mainland China.
- NO.1 Smart TechnologyminorKorea distribution partner for Humabiologics products in the South Korean market.
- GrandBiominorKorea distribution partner serving the South Korean market alongside NO.1 Smart Technology.
- FoliBiominorTaiwan distribution partner handling sales and distribution of Humabiologics products in Taiwan.
- Fisher ScientificcoreMajor US laboratory supplies distributor providing broad market access for Humabiologics products to research institutions and companies.
- VWRcoreLaboratory supply distribution partner serving research customers across the United States.
- Millipore SigmacoreLaboratory supply distribution partner providing access to research customers through established distribution network.
- Regemat 3DminorSpain distribution partner specializing in 3D bioprinting products and solutions for the Spanish market.
- BrinterminorFinland distribution partner for 3D bioprinting and biomaterial products serving the Nordic market.
- URMAT BiomedicalminorSlovenia distribution partner serving the Central European market for biomaterials and regenerative medicine products.
Scale indicators3 records
Recent moves7 records
Expansion highlights6 records
Humabiologics competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Humabiologics social profiles
Digital presenceHumabiologics compliance and trust
Trust signalCompliance3 records
Humabiologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Humabiologics leadership team
Management profileNumber of profiles
Profiles2 records
Humabiologics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Humabiologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Humabiologics
What does Humabiologics do?
Humabiologics manufactures and sells native human-derived biomaterials — including collagen (Types I, II, IV, V), gelatin, elastin, and tissue- and organ-specific extracellular matrix (ECM) products — for regenerative medicine research. Products are produced from donated human tissues sourced from AATB-accredited tissue banks under ISO 13485 cGMP standards and sold as research reagents in solution, lyophilized, insoluble, methacrylated, and pre-coated cultureware formats. The portfolio supports applications such as 2D/3D cell culture, organoids, bioprinting, bioinks, disease modeling, organ-on-chip, and drug testing.
Is Humabiologics a public or private company?
Humabiologics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Humabiologics founded?
Humabiologics was founded in 2018. It employs 11 to 50 people.
Where is Humabiologics based?
Humabiologics is headquartered in Phoenix, United States, in the North America region.
How does Humabiologics make money?
One revenue line is on record: biomaterial product sales.
Does Humabiologics have an API?
No public API is recorded for Humabiologics.
What industry is Humabiologics in?
Humabiologics's product category is Regenerative Medicine Biomaterials. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAC, 3D Bioprinting & Biofabrication. Its NAICS code is 325414 and its SIC code is 2836.